Targeting protein-protein interactions: A promising avenue of anti-HIV drug discovery

Current Medicinal Chemistry

Volumn 17, Issue 29, 2010, Pages 3393-3409

  Zhan, Peng ^a   Li, Wenjun ^a   Chen, Hongfei ^a   Liu, Xinyong ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

AIDS; Drug design; Drug targets; HIV; Inhibitor; Protein protein interactions

Indexed keywords

1 (4 BENZOYLPIPERAZIN 1 YL) 2 (1H INDOL 3 YL)ETHANE 1,2 DIONE; 1 BENZOYL 4 [(4,7 DIMETHOXY 1H PYRROLO[2,3 C]PYRIDIN 3 YL)OXOACETYL]PIPERAZINE; 4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; ANTIMONY DERIVATIVE; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; CARBIMAZOLE; CD4 ANTIGEN; EXPORTIN 1; GAG PROTEIN; GLYCOPROTEIN GP 120; LIPOPEPTIDE; NBD 556; NBD 557; NSC 13755; NSC 13759; NSC 13778; PEPTIDOMIMETIC AGENT; PKF 050638; PROTEINASE INHIBITOR; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN; UNCLASSIFIED DRUG; VPR PROTEIN; ZINTEVIR;

ARTICLE; CLINICAL TRIAL; DIMERIZATION; DRUG DESIGN; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION;

EID: 77957931762     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710793176357     Document Type: Article

References (179)

1. AIDS Epidemic Update: December 2009. Joint United Nations Programme on HIV/AIDS and World Health Organization 2009.
2. De Clercq, E. The history of antiretrovirals: key discoveries over the past 25 years. Rev. Med. Virol., 2009, 19, 287-299.
3. De Clercq, E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int. J. Antimicrob. Agents, 2009, 33, 307-320.
4. De Clercq, E. The design of drugs for HIV and HCV. Nat. Rev. Drug Discov., 2007, 6, 1001-1018.
5. Zhan, P.; Liu, X. Designed multiple ligands: an emerging anti-HIV drug discovery paradigm. Curr. Pharm. Des., 2009, 15, 1893-1917.
6. Zhan, P.; Liu, X.; Li, Z, Pannecouque C, De Clercq E. Design strategies of novel NNRTIs to overcome drug resistance. Curr. Med. Chem., 2009, 16, 3903-3917.
7. Greene, W.C.; Debyser, Z.; Ikeda, Y.; Freed, E.O.; Stephens, E.; Yonemoto, W.; Buckheit, R.W.; Esté, J.A.; Cihlar, T. Novel targets for HIV therapy. Antiviral Res., 2008, 80, 251-265.
8. Zhang, J.; Liu, X.; De Clercq, E. Capsid (CA) protein as a novel drug target: recent progress in the research of HIV-1 CA inhibitors. Mini. Rev. Med. Chem., 2009, 9, 510-518.
9. Mingyan, Y.; Xinyong, L.; De Clercq, E. NF-kappaB: the inducible factors of HIV-1 transcription and their inhibitors. Mini. Rev. Med. Chem., 2009, 9, 60-69.
10. Cao, Y.; Liu, X.; De Clercq, E. Cessation of HIV-1 transcription by inhibiting regulatory protein Rev-mediated RNA transport. Curr. HIV Res., 2009, 7, 101-108.
11. Yu, F.; Liu, X.; Zhan, P.; De Clercq, E. Recent advances in the research of HIV-1 RNase H inhibitors. Mini. Rev. Med. Chem., 2008, 8, 1243-1251.
12. Wang, Y.; Liu, X.Y.; De Clercq, E. Role of the HIV-1 positive elongation factor P-TEFb and inhibitors thereof. Mini. Rev. Med. Chem., 2009, 9, 379-385.
13. Chen, H.; Liu, X.; Li, Z.; Zhan, P.; De Clercq, E. TSG101: a novel anti-HIV-1 drug target. Curr. Med. Chem., 2010, 17, 750-758.
14. Zhan, P.; Liu, X.; De Clercq, E. Blocking nuclear import of pre-integration complex: an emerging anti-HIV-1 drug discovery paradigm. Curr. Med. Chem., 2010, 17, 495-503.
15. Vicent, M.J.; Pérez-Payá, E.; Orzáez, M. Discovery of inhibitors of protein-protein interactions from combinatorial libraries. Curr. Top Med. Chem., 2007, 7, 83-95.
16. Gerrard, J.A.; Hutton, C.A.; Perugini, M.A. Inhibiting protein-protein interactions as an emerging paradigm for drug discovery. Mini. Rev. Med. Chem., 2007, 7, 151-157.
17. Pagliaro, L.; Felding, J.; Audouze, K.; Nielsen, S.J.; Terry, R.B.; Krog-Jensen, C.; Butcher, S. Emerging classes of protein-protein interaction inhibitors and new tools for their development. Curr. Opin. Chem. Biol., 2004, 8, 442-449.
18. White, A.W.; Westwell, A.D.; Brahemi, G. Protein-protein interactions as targets for small-molecule therapeutics in cancer. Expert Rev. Mol. Med., 2008, 10, e8.
19. Berg, T. Small-molecule inhibitors of protein-protein interactions. Curr. Opin. Drug Discov. Devel., 2008, 11, 666-674.
20. Chène, P. Drugs targeting protein-protein interactions. ChemMedChem, 2006, 1, 400-411.
21. Zhao, L.; Chmielewski, J. Inhibiting protein-protein interactions using designed molecules. Curr. Opin. Struct. Biol., 2005, 15, 31-34.
22. Pommier, Y.; Cherfils, J. Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery. Trends Pharmacol. Sci., 2005, 26, 138-145.
23. Loregian, A.; Palù, G. Disruption of protein-protein interactions: towards new targets for chemotherapy. J. Cell Physiol., 2005, 204, 750-762.
24. Yin, H.; Hamilton, A.D. Strategies for targeting protein-protein interactions with synthetic agents. Angew. Chem. Int. Ed. Engl., 2005, 44, 4130-4163.
25. Fry, D.C. Drug-like inhibitors of protein-protein interactions: a structural examination of effective protein mimicry. Curr. Protein Pept. Sci., 2008, 9, 240-247.
26. Keskin, O.; Gursoy, A.; Ma, B.; Nussinov, R. Towards drugs targeting multiple proteins in a systems biology approach. Curr. Top Med. Chem., 2007, 7, 943-951.
27. Hershberger, S.J.; Lee, S.G.; Chmielewski, J. Scaffolds for blocking protein-protein interactions. Curr. Top Med. Chem., 2007, 7, 928-942.
28. Murray, J.K.; Gellman, S.H. Targeting protein-protein interactions: lessons from p53/MDM2. Biopolymers, 2007, 88, 657-686.
29. Toogood, P.L. Inhibition of protein-protein association by small molecules: approaches and progress. J. Med. Chem., 2002, 45, 1543-1558.
30. Ivanov, A.S.; Gnedenko, O.V.; Molnar, A.A.; Mezentsev, Y.V.; Lisitsa, A.V.; Archakov, A.I. Protein-protein interactions as new targets for drug design: virtual and experimental approaches. J. Bioinform. Comput. Biol., 2007, 5, 579-592.
31. Fletcher, S.; Hamilton, A.D. Targeting protein-protein interactions by rational design: mimicry of protein surfaces. J. R. Soc. Interface, 2006, 3, 215-233.
32. González-Ruiz, D.; Gohlke, H. Targeting protein-protein interactions with small molecules: challenges and perspectives for computational binding epitope detection and ligand finding. Curr. Med. Chem., 2006, 13, 2607-2625.
33. Fletcher, S.; Hamilton, A.D. Protein-protein interaction inhibitors: small molecules from screening techniques. Curr. Top Med. Chem., 2007, 7, 922-927.
34. Trkola, A. HIV-host interactions: vital to the virus and key to its inhibition. Curr. Opin. Microbiol., 2004, 7, 555-559.
35. Komano, J.; Futahashi, Y.; Urano, E.; Miyauchi, K.; Murakami, T.; Matsuda, Z.; Yamamoto, N. The interaction of HIV-1 with the host factors. Jpn. J. Infect. Dis., 2005, 58, 125-130.
36. Raulin, J. Human immunodeficiency virus and host cell lipids. Interesting pathways in research for a new HIV therapy. Prog. Lipid. Res., 2002, 41, 27-65.
37. Busschots, K.; De Rijck, J.; Christ, F.; Debyser, Z. In search of small molecules blocking interactions between HIV proteins and intracellular cofactors. Mol. Biosyst., 2009, 5, 21-31.
38. Rice, A.P.; Sutton, R.E.; Targeting protein-protein interactions for HIV therapeutics. Future HIV Ther., 2007, 1, 369-385.
39. Rusconi, S.; Scozzafava, A.; Mastrolorenzo, A.; Supuran, C.T. New advances in HIV entry inhibitors development. Curr. Drug Targets Infect. Disord., 2004, 4, 339-355.
40. Qian, K.; Morris-Natschke, S.L.; Lee, K.H. HIV entry inhibitors and their potential in HIV therapy. Med. Res. Rev., 2009, 29, 369-393.
41. Tilton, J.C.; Doms, R.W. Entry Inhibitors in the Treatment of HIV-1 Infection. Antiviral Res., 2009, 85, 91-100.
42. Markovic, I.; Clouse, K.A. Recent advances in understanding the molecular mechanisms of HIV-1 entry and fusion: revisiting current targets and considering new options for therapeutic intervention. Curr. HIV. Res., 2004, 2, 223-234.
43. Vermeire, K.; Schols, D. Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor. Expert Opin. Investig. Drugs, 2005, 14, 1199-212.
44. Kwong, P.D.; Wyatt, R.; Robinson, J.; Sweet, R.W.; Sodroski, J.; Hendrickson, W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature, 1998, 393, 648-659.
45. Fontenot, J.D.; Tan, X.; Phillips, D.M. Structure-based design of peptides that recognize the CD4 binding domain of HIV-1 gp120. AIDS., 1998, 12, 1413-1418.
46. Boussard, C.; Doyle, V.E.; Mahmood, N.; Klimkait, T.; Pritchard, M.; Gilbert, I.H. Design, synthesis and evaluation of peptide libraries as potential anti-HIV compounds, via inhibition of gp120/cell membrane interactions, using the gp120/cd4/fab17 crystal structure. Eur. J. Med. Chem., 2002, 37, 883-890.
47. Boussard, C.; Klimkait, T.; Mahmood, N.; Pritchard, M.; Gilbert, I.H. Design, synthesis and evaluation of potential inhibitors of HIV gp120-CD4 interactions. Bioorg. Med. Chem. Lett., 2004, 14, 2673-2676.
48. Xie, H.; Ng, D.; Savinov, S.N.; Dey, B.; Kwong, P.D.; Wyatt, R.; Smith, AB 3rd.; Hendrickson, W.A. Structure-activity relationships in the binding of chemically derivatized CD4 to gp120 from human immunodeficiency virus. J. Med. Chem., 2007, 50, 4898-908.
49. Hurevich, M.; Swed, A.; Joubran, S.; Cohen, S.; Freeman, N. S.; Briant-Longuet, L.; Bardy, Ma.; Devaux, C.; Kotler, M.; Hofmann, A.; Gilon, C. Rational conversion of noncontinuous active region in proteins into a small orally bioavailable macrocyclic drug like molecule: the HIV-1 CD4:gp120 paradigm. Bioorg. Med. Chem., 2010, DOI: 10.1016/j.bmc.2010.04.053.
50. Caporuscio, F.; Tafi, A.; González, E.; Manetti, F.; Esté, J.A.; Botta, M. A dynamic target-based pharmacophoric model mapping the CD4 binding site on HIV-1 gp120 to identify new inhibitors of gp120-CD4 protein-protein interactions. Bioorg. Med. Chem. Lett., 2009, 19, 6087-6091.
51. Guo, L.; Heinzinger, N.K.; Stevenson, M.; Schopfer, L.M.; Salhany, J.M. Inhibition of gp120-CD4 interaction and human immunodeficiency virus type 1 infection in vitro by pyridoxal 5'-phosphate. Antimicrob. Agents Chemother., 1994, 38, 2483-2487.
52. Ojwang, J.O.; Buckheit, R.W.; Pommier, Y.; Mazumder, A.; De Vreese, K.; Este, J.A.; Reymen, D.; Pallansch, L.A.; Lackman-Smith, C.; Wallace, T.L.; De clercq, E.; Mcgrath, M.S.; Rando, R.F. T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob. Agents Chemother., 1995, 39, 2426-2435.
53. Este, J.A.; Cabrera, C.; Schols, D.; Cherepanov, P.; Gutierrez, A.; Witvrouw, M.; Pannecouque, C.; Debyser, Z.; Rando, R.F.; Clotet, B.; Desmyter, J.; De Clercq, E. Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir). Mol. Pharmacol., 1998, 53, 340-345.
54. Wallace, T.L.; Gamba-Vitalo, C.; Loveday, K.S.; Cossum, P.A. Acute, multiple-dose, and genetic toxicology of AR177, an anti-HIV oligonucleotide. Toxicol. Sci., 2000, 53, 63-70.
55. Wallace, T.L.; Bazemore, S.A.; Kornbrust, D.J.; Cossum, P.A. Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys. J. Pharmacol. Exp. Ther., 1996, 278, 1306-1312.
56. Weber, J.; Piontkivska, H.; Quinones-Mateu, M.E. HIV type 1 tropism and inhibitors of viral entry: Clinical implications. AIDS. Rev., 2006, 8, 60-77.
57. Yang, Q.E.; Stephen, A.G.; Adelsberger, J.W.; Roberts, P.E.; Zhu, W.; Currens, M.J.; Feng, Y.; Crise, B.J.; Gorelick, R.J.; Rein, A.R.; Fisher, R.J.; Shoemaker, R.H.; Sei, S. Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4. J. Virol., 2005, 79, 6122-6133.
58. Wang, T.; Zhang, Z.; Wallace, O.B.; Deshpande, M.; Fang, H.; Yang, Z.; Zadjura, L.M.; Tweedie, D.L.; Huang, S.; Zhao, F.; Ranadive, S.; Robinson, B.S.; Gong, Y.F.; Ricarrdi, K.; Spicer, T.P.; Deminie, C.; Rose, R.; Wang, H.G.; Blair, W.S.; Shi, P.Y.; Lin, P.F.; Colonno, R.J.; Meanwell, N.A. Discovery of 4-benzoyl-1- [(4-methoxy-1H-pyrrolo [2,3-b]pyridin-3-yl) oxoacetyl]-2-(R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J. Med. Chem., 2003, 46, 4236-4239.
59. Meanwell, N.A.; Wallace, O.B.; Fang, H.; Wang, H.; Deshpande, M.; Wang, T.; Yin, Z.; Zhang, Z.; Pearce, B.C.; James, J.; Yeung, K.S.; Qiu, Z.; Kim Wright, J.J.; Yang, Z.; Zadjura, L.; Tweedie, D.L.; Yeola, S.; Zhao, F.; Ranadive, S.; Robinson, B.A.; Gong, Y.F.; Wang, H.G.; Blair, W.S.; Shi, P.Y.; Colonno, R.J.; Lin, P.F. Inhibitors of HIV-1 attachment. Part 2: An initial survey of indole substitution patterns. Bioorg. Med. Chem. Lett., 2009, 19, 1977-1981.
60. Meanwell, N.A.; Wallace, O.B.; Wang, H.; Deshpande, M.; Pearce, B.C.; Trehan, A.; Yeung, K.S.; Qiu, Z.; Wright, J.J.; Robinson, B.A.; Gong, Y.F.; Wang, H.G.; Blair, W.S.; Shi, P.Y.; Lin, P.F. Inhibitors of HIV-1 attachment. Part 3: A preliminary survey of the effect of structural variation of the benzamide moiety on antiviral activity. Bioorg. Med. Chem. Lett., 2009, 19, 5136-5139.
61. Wang, T.; Kadow, J.F.; Zhang, Z.; Yin, Z.; Gao, Q.; Wu, D.; Parker, D.D.; Yang, Z.; Zadjura, L.; Robinson, B.A.; Gong, Y.F.; Blair, W.S.; Shi, P.Y; Yamanaka, G.; Lin, P.F.; Meanwell, N.A. Inhibitors of HIV-1 attachment. Part 4: A study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives. Bioorg. Med. Chem. Lett., 2009, 19, 5140-5145.
62. Lin, P.F.; Blair, W.; Wang, T.; Spicer, T.; Guo, Q.; Zhou, N.; Gong, Y.F.; Wang H.G.; Rose, R.; Yamanaka, G.; Robinson, B.; Li, C.B.; Fridell, R.; Deminie, C.; Demers, G.; Yang, Z.; Zadjura, L.; Meanwell, N.; Colonno, R. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. USA., 2003, 100, 11013-11018.
63. Guo, Q.; Ho, H.T.; Dicker, I.; Fan, L.; Zhou, N.; Friborg, J.; Wang, T.; McAuliffe, B.V.; Wang, H.G.; Rose, R.E.; Fang, H.; Scarnati, H.T.; Langley, D.R.; Meanwell, N.A.; Abraham, R.; Colonno, R.J.; Lin, P.F. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J. Virol., 2003, 77, 10528-10536.
64. Ho, H.T.; Fan, L.; Nowicka-Sans, B.; McAuliffe, B.; Li, C.B.; Yamanaka, G.; Zhou, N.; Fang, H.; Dicker, I.; Dalterio, R.; Gong, Y.F.; Wang, T.; Yin, Z.; Ueda, Y.; Matiskella, J.; Kadow, J.; Clapham, P.; Robinson, J.; Colonno, R.; Lin, P.F. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events. J. Virol., 2006, 80, 4017-4025.
65. Si Z.; Madani, N.; Cox, J.M.; Chruma, J.J.; Klein, J.C.; Schon, A.; Phan, N.; Wang, L.; Biorn, A.C.; Cocklin, S.; Chaiken, I.; Freire, E.; Smith, AB III.; Sodroski, J.G. Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc. Natl. Acad. Sci. USA., 2004, 101, 5036-5041.
66. Kadow J., Wang, H.G., Lin P.F. Small-molecule HIV-1 gp120 inhibitors to prevent HIV-1 entry: An emerging opportunity for drug development. Curr. Opin. Investig. Drugs, 2006, 7, 721-726.
67. Wang, T.; Yin, Z.; Zhang, Z.; Bender, J.A.; Yang, Z.; Johnson, G.; Yang, Z.; Zadjura, L.M.; D'Arienzo, C.J.; Di Giugno Parker, D.; Gesenberg, C.; Yamanaka, G.A.; Gong, Y.F.; Ho, H.T.; Fang, H.; Zhou, N.; McAuliffe, B.V.; Eggers, B.J.; Fan, L.; Nowicka-Sans, B.; Dicker, I.B.; Gao Q.; Colonno, R.J.; Lin, P.F.; Meanwell, N.A.; Kadow, J.F. Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo [2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects. J. Med. Chem., 2009, 52, 7778-7787.
68. Zhao, Q.; Ma, L.; Jiang, S.; Lu, H.; Liu, S.; He, Y.; Strick, N.; Neamati, N.; Debnath, A.K. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology, 2005, 339, 213-225.
69. (a) WO-2005016344; (b) WO-2005121094.
70. Williams, D.H.; Adam, F.; Fenwick, D.R.; Fok-Seang, J.; Gardner, I.; Hay, D.; Jaiessh, R.; Middleton, D.S.; Mowbray, C.E.; Parkinson, T.; Perros, M.; Pickford, C.; Platts, M.; Randall, A.; Siddle, D.; Stephenson, P.T.; Tran, T.D.; Vuong, H. Discovery of a small molecule inhibitor through interference with the gp120-CD4 interaction. Bioorg. Med. Chem. Lett., 2009, 19, 5246-5249.
71. Tran, T.D.; Adam, F.M.; Calo, F.; Fenwick, D.R.; Fok-Seang, J.; Gardner, I.; Hay, D.A.; Perros, M.; Rawal, J.; Middleton, D.S.; Parkinson, T.; Pickford, C.; Platts, M.; Randall, A.; Stephenson, P.T.; Vuong, H.; Williams, D.H. Design and optimisation of potent gp120-CD4 inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 5250-5255.
72. Allaway, G.P.; Davis-Bruno, K.L.; Beaudry, G.A.; Garcia, E.B.; Wong, E.L.; Ryder, A.M.; Hasel, K.W.; Gauduin, M.C.; Koup, R.A.; McDougal, J.S.; Maddon, P.J. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS. Res. Hum. Retroviruses, 1995, 11, 533-539.
73. Jacobson, J.M.; Israel, R.J.; Lowy, I.; Ostrow, N.A.; Vassilatos, L.S.; Barish, M.; Tran, D.N.; Sullivan, B.M.; Ketas, T.J.; O'Neill, T.J.; Nagashima, K.A.; Huang, W.; Petropoulos, C.J.; Moore, J.P.; Maddon, P.J.; Olson, W.C. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob. Agents Chemother., 2004, 48, 423-429.
74. Jacobson, J.M.; Lowy, I.; Fletcher, C.V.; O'Neill, T.J.; Tran, D.N.; Ketas, T.J.; Trkola, A.; Klotman, M.E.; Maddon, P.J.; Olson, W.C.; Israel, R.J. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J. Infect. Dis., 2000, 182, 326-329.
75. Moore, J.P.; Sattentau, Q.J.; Klasse, P.J.; Burkly, L.C. A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4t cells. J. Virol., 1992, 66, 4784-4793.
76. Kuritzkes, D.R.; Jacobson, J.; Powderly, W.G.; Godofsky, E.; DeJesus, E.; Haas, F.; Reimann, K.A.; Larson, J.L.; Yarbough, P.O.; Curt, V.; Shanahan, WR Jr. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J. Infect. Dis., 2004, 189, 286-291.
77. Neffe, A.T.; Meyer, B. A peptidomimetic HIV-entry inhibitor directed against the CD4 binding site of the viral glycoprotein gp120. Angew. Chem. Int. Ed. Engl., 2004, 43, 2937-2940.
78. Pattyn, E.; Lavens, D.; Van der Heyden, J.; Verhee, A.; Lievens, S.; Lemmens, I.; Hallenberger, S.; Jochmans, D.; Tavernier, J. MAPPIT (MAmmalian Protein-Protein Interaction Trap) as a tool to study HIV reverse transcriptase dimerization in intact human cells. J. Virol. Methods, 2008, 153, 7-15.
79. Camarasa, M.J.; Velázquez, S.; San-Félix, A.; Pérez-Pérez, M.J.; Gago, F. Dimerization inhibitors of HIV-1 reverse transcriptase, protease and integrase: a single mode of inhibition for the three HIV enzymes? Antiviral Res., 2006, 71, 260-267.
80. Srivastava, S.; Sluis-Cremer, N.; Tachedjian, G. Dimerization of human immunodeficiency virus type 1 reverse transcriptase as an antiviral target. Curr. Pharm. Des., 2006, 12, 1879-1894.
81. Tachedjian, G.; Goff, S.P. The effect of NNRTIs on HIV reverse transcriptase dimerization. Curr. Opin. Investig. Drugs, 2003, 4, 966-973.
82. Camarasa, M.J.; Velázquez, S.; San-Félix, A.; Pérez-Pérez, M.J.; Bonache, M.C.; De Castro, S. TSAO derivatives, inhibitors of HIV-1 reverse transcriptase dimerization: recent progress. Curr. Pharm. Des., 2006, 12, 1895-1907.
83. Camarasa, M.J.; Velázquez, S.; San-Félix, A.; Pérez-Pérez, M.J. TSAO derivatives the first non-peptide inhibitors of HIV-1 RT dimerization. Antivir. Chem. Chemother., 2005, 16, 147-153.
84. Camarasa, M.J.; San-Félix, A.; Velázquez, S.; Pérez-Pérez, M.J.; Gago, F.; Balzarini, J. TSAO compounds: the comprehensive story of a unique family of HIV-1 specific inhibitors of reverse transcriptase. Curr. Top Med. Chem., 2004, 4, 945-963.
85. Bonache, M.C.; Quesada, E.; Sheen, C.W.; Balzarini, J.; Sluis-Cremer, N.; Pérez-Pérez, M.J.; Camarasa, M.J.; San-Félix, A. Novel N-3 substituted TSAO-T derivatives: synthesis and anti-HIV-evaluation. Nucleosides Nucleotides Nucleic Acids, 2008, 27, 351-367.
86. Tomassi, C.; Nguyen, V.N.; Marco-Contelles, J.; Balzarini, J.; Pannecouque, C.; De Clercq, E.; Soriano, E.; Postel, D. Synthesis, anti-HIV-1 activity, and modeling studies of N-3 Boc TSAO compound. Bioorg. Med. Chem. Lett., 2008, 18, 2277-2281.
87. Tomassi, C.; Nguyen Van Nhien, A.; Marco-Contelles, J.; Balzarini, J.; Pannecouque, C.; De Clercq, E.; Postel, D. Synthesis and anti-HIV1 biological activity of novel 5''-ATSAO compounds. Bioorg. Med. Chem., 2008, 16, 4733-4741.
88. de Castro, S.; Andrei, G.; Snoeck, R.; Balzarini, J.; Camarasa, M.J.; Velázquez, S. Novel non-nucleoside human cytomegalovirus inhibitors based upon TSAO nucleoside derivatives: structure-activity relationships. Nucleosides Nucleotides Nucleic Acids, 2007, 26, 625-628.
89. Sluis-Cremer, N.; Hamamouch, N.; San Félix, A.; Velazquez, S.; Balzarini, J.; Camarasa, M.J. Structure-activity relationships of [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5-(4-amino-1,2-oxathiole-2,2-dioxide)thymine derivatives as inhibitors of HIV-1 reverse transcriptase dimerization. J. Med. Chem., 2006, 49, 4834-4841.
90. Soriano, E.; Marco-Contelles, J.; Tomassi, C.; Nguyen Van Nhien, A.; Postel, D. Computational analysis of aza analogues of [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-Dribofuranose]-3'-spiro-5-(4-amino-1,2-oxathiole-2,2-dioxide) (TSAO) as HIV-1 reverse transcriptase inhibitors: relevance of conformational properties on the inhibitory activity. J. Chem. Inf. Model, 2006, 46, 1666-1677.
91. de Castro, S.; García-Aparicio, C.; Van Laethem, K.; Gago, F.; Lobatón, E.; De Clercq, E.; Balzarini, J.; Camarasa, M.J.; Velázquez, S. Discovery of TSAO derivatives with an unusual HIV-1 activity/resistance profile. Antiviral Res., 2006, 71, 15-23.
92. Bonache, M.C.; Chamorro, C.; Velázquez, S.; De Clercq, E.; Balzarini, J.; Barrios, F.R.; Gago, F.; Camarasa, M.J.; San-Félix, A. Improving the antiviral efficacy and selectivity of HIV-1 reverse transcriptase inhibitor TSAO-T by the introduction of functional groups at the N-3 position. J. Med. Chem., 2005, 48, 6653-6660.
93. Nguyen Van Nhien, A.; Tomassi, C.; Len, C.; Marco-Contelles, J.L.; Balzarini, J.; Pannecouque, C.; De Clercq, E.; Postel, D. First synthesis and evaluation of the inhibitory effects of aza analogues of TSAO on HIV-1 replication. J. Med. Chem., 2005, 48, 4276-4284.
94. Bonache, M.C.; Chamorro, C.; Velázquez, S.; De Clercq, E.; Balzarini, J.; Camarasa, M.J.; San-Félix, A. N-3 substituted TSAO derivatives as a probe to explore the dimeric interface of HIV-1 reverse transcriptase. Nucleosides Nucleotides Nucleic Acids, 2003, 22, 947-949.
95. Rodríguez-Barrios, F.; Pérez, C.; Lobatón, E.; Velázquez, S.; Chamorro, C.; San-Félix, A.; Pérez-Pérez, M.J.; Camarasa, M.J.; Pelemans, H.; Balzarini, J.; Gago, F. Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase. J. Med. Chem., 2001, 44, 1853-1865.
96. Sluis-Cremer, N.; Arion, D.; Parniak, M.A. Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors. Mol. Pharmacol., 2002, 62, 398-405.
97. Grohmann, D.; Corradi, V.; Elbasyouny, M.; Baude, A.; Horenkamp, F.; Laufer, S.D.; Manetti, F.; Botta, M.; Restle, T. Small molecule inhibitors targeting HIV-1 reverse transcriptase dimerization. Chembiochem, 2008, 9, 916-922.
98. Balzarini, J.; Auwerx, J.; Rodríguez-Barrios, F.; Chedad, A.; Farkas, V.; Ceccherini-Silberstein, F.; García-Aparicio, C.; Velázquez, S.; De Clercq, E.; Perno, C.F.; Camarasa, M.J.; Gago, F. The amino acid Asn136 in HIV-1 reverse transcriptase (RT) maintains efficient association of both RT subunits and enables the rational design of novel RT inhibitors. Mol. Pharmacol., 2005, 68, 49-60.
99. Mulky, A.; Vu, B.C.; Conway, J.A.; Hughes, S.H.; Kappes, J.C. Analysis of amino acids in the 7-8 loop of human immunodeficiency virus type 1 reverse transcriptase for their role in virus replication. J. Mol. Biol., 2007, 365, 1368-1378.
100. Navia, M. A.; Fitzgerald, P. M.; McKeever, B. M.; Leu, C. T.; Heimbach, J. C. Herber, W. K., Sigal, I. S., Darke, P. L., Springer, J. P. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature. 1989, 337, 615-620.
101. Gulnik, S.; Erickson, J.W.; Xie, D. HIV protease: enzyme function and drug resistance. Vitam. Horm., 2000, 58, 213-256.
102. Frutos, S.; Rodriguez-Mias, R.A.; Madurga, S.; Collinet, B.; Reboud-Ravaux, M.; Ludevid, D.; Giralt, E. Disruption of the HIV-1 protease dimer with interface peptides: structural studies using NMR spectroscopy combined with [2-(13)C]-Trp selective labeling. Biopolymers, 2007, 88, 164-173.
103. Bannwarth, L.; Reboud-Ravaux, M. An alternative strategy for inhibiting multidrug-resistant mutants of the dimeric HIV-1 protease by targeting the subunit interface. Biochem. Soc. Trans., 2007, 35, 551-554.
104. Small molecule inhibitors of HIV protease dimerization for use in treatment of HIV infection and AIDS. PCT Int. Appl. (2008), 127pp. CODEN:PIXXD2; WO2008133734.
105. Broglia, R.A.; Provasi, D.; Vasile, F.; Ottolina, G.; Longhi, R.; Tiana, G. A folding inhibitor of the HIV-1 protease. Proteins, 2006, 62, 928-933.
106. Davis, D.A.; Brown, C.A.; Singer, K.E.; Wang, V.; Kaufman, J.; Stahl, S.J.; Wingfield, P.; Maeda, K.; Harada, S.; Yoshimura, K.; Kosalaraksa, P.; Mitsuya, H.; Yarchoan, R. Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease. Antiviral Res., 2006, 72, 89-99.
107. Boggetto, N.; Reboud-Ravaux, M. Dimerization inhibitors of HIV-1 protease. Biol. Chem., 2002, 383, 1321-1324.
108. Bowman, M.J.; Chmielewski, J. Novel strategies for targeting the dimerization interface of HIV protease with cross-linked interfacial peptides. Biopolymers, 2002, 66, 126-133.
109. Zutshi, R.; Chmielewski, J. Targeting the dimerization interface for irreversible inhibition of HIV-1 protease. Bioorg. Med. Chem. Lett., 2000, 10, 1901-1903.
110. Quéré, L.; Wenger, T.; Schramm, H.J. Triterpenes as potential dimerization inhibitors of HIV-1 protease. Biochem. Biophys. Res. Commun., 1996, 227, 484-488.
111. Schramm, H.J.; de Rosny, E.; Reboud-Ravaux, M.; Büttner, J.; Dick, A.; Schramm, W. Lipopeptides as dimerization inhibitors of HIV-1 protease. Biol. Chem., 1999, 380, 593-596.
112. Breccia, P.; Boggetto, N.; Pérez-Fernández, R.; Van Gool, M.; Takahashi, M.; René, L.; Prados, P.; Badet, B.; Reboud-Ravaux, M.; de Mendoza, J. Dimerization inhibitors of HIV-1 protease based on a bicyclic guanidinium subunit. J. Med. Chem., 2003, 46, 5196-5207.
113. Koh, Y.; Matsumi, S.; Das, D.; Amano, M.; Davis, D.A.; Li, J.; Leschenko, S.; Baldridge, A.; Shioda, T.; Yarchoan, R.; Ghosh, A.K.; Mitsuya, H. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J. Biol. Chem., 2007, 282, 28709-28720.
114. Bouras, A.; Boggetto, N.; Benatalah, Z.; de Rosny, E.; Sicsic, S.; Reboud-Ravaux, M. Design, synthesis, and evaluation of conformationally constrained tongs, new inhibitors of HIV-1 protease dimerization. J. Med. Chem., 1999, 42, 957-962.
115. Song, M.; Rajesh, S.; Hayashi, Y.; Kiso, Y. Design and synthesis of new inhibitors of HIV-1 protease dimerization with conformationally constrained templates. Bioorg. Med. Chem. Lett., 2001, 11, 2465-2468.
116. Shultz, M. D.; Bowman, M. J.; Ham, Y. W.; Zhao, X.; Tora, G.; Chmielewski, J. Small-Molecule Inhibitors of HIV-1 Protease Dimerization Derived from Cross-Linked Interfacial Peptides This work was supported by NIH (GM52739) and NSF (9457372-CHE). Angew. Chem. Int. Ed. 2000, 39, 2710-2713.
117. Hwang, Y.S.; Chmielewski, J. A unidirectional crosslinking strategy for HIV-1 protease dimerization inhibitors. Bioorg. Med. Chem. Lett., 2004, 14, 4297-4300.
118. Hwang, Y.S.; Chmielewski, J. Development of low molecular weight HIV-1 protease dimerization inhibitors. J. Med. Chem., 2005, 48, 2239-2242.
119. Bowman, M.J.; Chmielewski, J. Crucial amides for dimerization inhibitors of HIV-1 protease. Bioorg. Med. Chem. Lett., 2004, 14, 1395-1398.
120. Shultz, M.D.; Ham, Y.W.; Lee, S.G.; Davis, D.A.; Brown, C.; Chmielewski, J. Small-molecule dimerization inhibitors of wildtype and mutant HIV protease: a focused library approach. J. Am. Chem. Soc., 2004, 126, 9886-7.
121. Bowman, M.J.; Byrne, S.; Chmielewski, J. Switching between allosteric and dimerization inhibition of HIV-1 protease. Chem. Biol., 2005, 12, 439-444.
122. Lee, S.G.; Chmielewski, J. Rapid synthesis and in situ screening of potent HIV-1 protease dimerization inhibitors. Chem. Biol., 2006, 13, 421-426.
123. Bowman, M.J.; Chmielewski, J. Sidechain-linked inhibitors of HIV-1 protease dimerization. Bioorg. Med. Chem., 2009, 17, 967-976.
124. Chiu, T.K.; Davies, DR. Structure and function of HIV-1 integrase. Curr. Top Med. Chem., 2004, 4, 965-977.
125. Delelis, O.; Carayon, K.; Saïb, A.; Deprez, E.; Mouscadet, J.F. Integrase and integration: biochemical activities of HIV-1 integrase. Retrovirology, 2008, 5, 114.
126. Zeinalipour-Loizidou, E.; Nicolaou, C.; Nicolaides, A.; Kostrikis, L.G. HIV-1 integrase: from biology to chemotherapeutics. Curr. HIV Res., 2007, 5, 365-388.
127. Maroun, R.G.; Gayet, S.; Benleulmi, M.S.; Porumb, H.; Zargarian, L.; Merad, H.; Leh, H.; Mouscadet, J.F.; Troalen, F.; Fermandjian, S. Peptide inhibitors of HIV-1 integrase dissociate the enzyme oligomers. Biochemistry, 2001, 40, 13840-13848.
128. Krajewski, K.; Long, Y.Q.; Marchand, C.; Pommier, Y.; Roller, P.P. Design and synthesis of dimeric HIV-1 integrase inhibitory peptides. Bioorg. Med. Chem. Lett., 2003, 13, 3203-3205.
129. Zhao, L.; O'Reilly, M.K.; Shultz, M.D.; Chmielewski, J. Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization. Bioorg. Med. Chem. Lett., 2003, 13, 1175-1177.
130. Molteni, V.; Greenwald, J.; Rhodes, D.; Hwang, Y.; Kwiatkowski, W.; Bushman, F.D.; Siegel, J.S.; Choe, S. Identification of a small-molecule binding site at the dimer interface of the HIV integrase catalytic domain. Acta. Crystallogr. D Biol. Crystallogr., 2001, 57, 536-544.
131. Carr, J.M.; Davis, A.J.; Feng, F.; Burrell, C.J.; Li, P. Cellular interactions of virion infectivity factor (Vif) as potential therapeutic targets: APOBEC3G and more? Curr. Drug Targets, 2006, 7, 1583-1593.
132. Barraud, P.; Paillart, J.C.; Marquet, R.; Tisné, C. Advances in the structural understanding of Vif proteins. Curr. HIV Res., 2008, 6, 91-99.
133. Mehle, A.; Wilson, H.; Zhang, C.; Brazier, A.J.; McPike, M.; Pery, E.; Gabuzda, D. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J. Virol., 2007, 81, 13235-13241.
134. Nathans, R.; Cao, H.; Sharova, N.; Ali, A.; Sharkey, M.; Stranska, R.; Stevenson, M.; Rana, T.M. Small-molecule inhibition of HIV-1 Vif. Nat. Biotechnol., 2008, 26, 1187-1192.
135. Al-Mawsawi, L.Q.; Neamati, N. Blocking interactions between HIV-1 integrase and cellular cofactors: An emerging anti-retroviral strategy. Trends Pharmacol. Sci., 2007, 28, 526-535.
136. Van Maele, B.; Busschots, K.; Vandekerckhove, L.; Christ, F.; Debyser, Z. Cellular co-factors of HIV-1 integration. Trends Biochem. Sci., 2006, 31, 98-105.
137. Ciuffi, A.; Bushman, F.D. Retroviral DNA integration: HIV and the role of LEDGF/p75. Trends Genet., 2006, 22, 388-395.
138. Poeschla, E.M. Integrase, LEDGF/p75 and HIV replication. Cell Mol. Life Sci., 2008, 65, 1403-1424.
139. De Clercq, E. The next ten stories on antiviral drug discovery (part E): Advents, Advances, and Adventures. Med. Res. Rev., 2009, on line: DOI 10.1002/med.20179.
140. Du, L.; Zhao, Y.; Chen, J.; Yang, L.; Zheng, Y.; Tang, Y.; Shen, X.; Jiang, H. D77, one benzoic acid derivative, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75. Biochem. Biophys. Res. Commun., 2008, 375, 139-144.
141. De Luca, L.; Barreca, M.L.; Ferro, S.; Christ, F.; Iraci, N.; Gitto, R.; Monforte, A.M.; Debyser, Z.; Chimirri, A. Pharmacophore-based discovery of small-molecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75. ChemMedChem, 2009, 4, 1311-1316.
142. Christ, F.; Voet, A.; Marchand, A.; Nicolet, S.; Desimmie, B.A.; Marchand, D.; Bardiot, D.; Van der Veken, N.J.; Van Remoortel, B.; Strelkov, S.V.; De Maeyer, M.; Chaltin, P.; Debyser, Z. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat. Chem. Biol., 2010, May 16. doi: 10.1038/nchembio.370
143. Hou, Y.; McGuinness, D.E.; Prongay, A.J.; Feld, B.; Ingravallo, P.; Ogert, R.A.; Lunn, C.A.; Howe, J.A. Screening for antiviral inhibitors of the HIV integrase-LEDGF/p75 interaction using the AlphaScreen luminescent proximity assay. J. Biomol. Screen, 2008, 13, 406-414.
144. Mekouar, K.; Mouscadet, J.F.; Desmaële, D.; Subra, F.; Leh, H.; Savouré, D.; Auclair, C.; d'Angelo, J. Styrylquinoline derivatives: a new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells. J. Med. Chem., 1998, 41, 2846-2857.
145. Mousnier, A.; Leh, H.; Mouscadet, J.F.; Dargemont, C. Nuclear import of HIV-1 integrase is inhibited in vitro by styrylquinoline derivatives. Mol. Pharmacol., 2004, 66, 783-788.
146. Christ, F.; Thys, W.; De Rijck, J.; Gijsbers, R.; Albanese, A.; Arosio, D.; Emiliani, S.; Rain, J.C.; Benarous, R.; Cereseto, A.; Debyser, Z. Transportin-SR2 imports HIV into the nucleus. Curr. Biol., 2008, 18, 1192-202.
147. Luban, J. HIV-1 infection: going nuclear with TNPO3/Transportin-SR2 and integrase. Curr. Biol., 2008, 18, R710-R713.
148. Woodward, C.L.; Prakobwanakit, S.; Mosessian, S.; Chow, S.A. Integrase interacts with nucleoporin NUP153 to mediate the nuclear import of human immunodeficiency virus type 1. J. Virol., 2009, 83, 6522-6533.
149. Di Fenza, A.; Rocchia, W.; Tozzini, V. Complexes of HIV-1 integrase with HAT proteins: Multiscale models, dynamics, and hypotheses on allosteric sites of inhibition. Proteins, 2009, 76, 946-958.
150. Thys, W.; Busschots, K.; McNeely, M.; Voet, A.; Christ, F.; Debyser, Z. LEDGF/p75 and transportin-SR2 are cellular cofactors of HIV integrase and novel targets for antiviral therapy. Future HIV Ther., 2009, 3, 171-188.
151. Engelman, A. Host cell factors and HIV-1 integration. Future HIV Ther., 2007, 1, 415-426.
152. Romani, B.; Engelbrecht, S. Human immunodeficiency virus type 1 Vpr: functions and molecular interactions. J. Gen. Virol., 2009, 90, 1795-1805.
153. Thieu, K.P.; Morrow, M.P.; Shedlock, D.J.; Schoenly, K.A.; Mallilankaraman, K.; Choo, A.Y.; Fagone, P.; Weiner, D.B.; Muthumani, K. HIV-1 Vpr: regulator of viral survival. Curr. HIV Res., 2009, 7, 153-162.
154. Suzuki, T.; Yamamoto, N.; Nonaka, M.; Hashimoto, Y.; Matsuda, G.; Takeshima, S.N.; Matsuyama, M.; Igarashi, T.; Miura, T.; Tanaka, R.; Kato, S.; Aida, Y. Inhibition of human immunodeficiency virus type 1 (HIV-1) nuclear import via Vpr-Importin alpha interactions as a novel HIV-1 therapy. Biochem. Biophys. Res. Commun., 2009, 380, 838-843.
155. Morellet, N.; Roques, B.P.; Bouaziz, S. Structure-function relationship of Vpr: biological implications. Curr. HIV Res., 2009, 7, 184-210.
156. Li, G.; Bukrinsky, M.; Zhao, R.Y. HIV-1 viral protein R (Vpr) and its interactions with host cell. Curr. HIV Res., 2009, 7, 178-183.
157. Zander, K.; Sherman, M.P.; Tessmer, U.; Bruns, K.; Wray, V.; Prechtel, A.T.; Schubert, E.; Henklein, P.; Luban, J.; Neidleman, J.; Greene, W.C.; Schubert, U. Cyclophilin A interacts with HIV-1 Vpr and is required for its functional expression. J. Biol. Chem., 2003, 278, 43202-43213.
158. Luban, J.; Bossolt, K.L.; Franke, E.K.; Kalpana, G.V.; Goff, S.P. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell, 1993, 73, 1067-1078.
159. Endrich, M.M.; Gehring, H. The V3 loop of human immunodeficiency virus type-1 envelope protein is a high-affinity ligand for immunophilins present in human blood. Eur. J. Biochem., 1998, 252, 441-446.
160. Braaten, D.; Luban, J. Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells. EMBO J., 2001, 20, 1300-1309.
161. Steinkasserer, A.; Harrison, R.; Billich, A. Hammerschmid, F.; Werner, G.; Wolff, B.; Peichl, P.; Palfi, G.; Schnitzel, W.; Mlynar, E.; Rosenwirth, B. Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus type 1 (HIV-1): interference with early and late events in HIV-1 replication. J. Virol., 1995, 69, 814-24.
162. Billich, A.; Hammerschmid, F.; Peichl, P.; Wenger, R.; Zenke, G.; Quesniaux, V.; Rosenwirth, B. Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein-cyclophilin A interactions. J. Virol., 1995, 69, 2451-2461.
163. Freed, E.O. The HIV-TSG101 interface: recent advances in a budding field. Trends Microbiol., 2003, 11, 56-59.
164. Tavassoli, A.; Lu, Q.; Gam, J.; Pan, H.; Benkovic, S.J.; Cohen, S.N. Inhibition of HIV budding by a genetically selected cyclic peptide targeting the Gag-TSG101 interaction. ACS Chem. Biol., 2008, 3, 757-764.
165. Waheed, A.A.; Freed, E.O. Peptide inhibitors of HIV-1 egress. ACS Chem. Biol., 2008, 3, 745-747.
166. Askjaer, P.; Jensen, T.H.; Nilsson, J.; Englmeier, L.; Kjems, J. The specificity of the CRM1-Rev nuclear export signal interaction is mediated by RanGTP. J. Biol. Chem., 1998, 273, 33414-33422.
167. Daelemans, D.; Afonina, E.; Nilsson, J.; Werner, G.; Kjems, J.; De Clercq, E.; Pavlakis, G.N.; Vandamme, A.M. A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc. Natl. Acad. Sci. U.S.A., 2002, 99, 14440-14445.
168. Van Neck, T.; Pannecouque, C.; Vanstreels, E.; Stevens, M.; Dehaen, W.; Daelemans, D. Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action. Bioorg. Med. Chem., 2008, 16, 9487-9497.
169. Abbott, K.L.; Archambault, J.; Xiao, H.; Nguyen, B.D.; Roeder, R.G.; Greenblatt, J.; Omichinski, J.G.; Legault, P. Interactions of the HIV-1 Tat and RAP74 proteins with the RNA polymerase II CTD phosphatase FCP1. Biochemistry, 2005, 44, 2716-2731.
170. Druillennec, S.; Caneparo, A.; de Rocquigny, H.; Roques, B.P. Evidence of interactions between the nucleocapsid protein NCp7 and the reverse transcriptase of HIV-1. J. Biol. Chem., 1999, 274, 11283-11288.
171. Schweneker, M.; Bachmann, A.S.; Moelling, K. The HIV-1 coreceptor CCR5 binds to alpha-catenin, a component of the cellular cytoskeleton. Biochem. Biophys. Res. Commun., 2004, 325, 751-757.
172. Roeth, J.F.; Williams, M.; Kasper, M.R.; Filzen, T.M.; Collins, K.L. HIV-1 Nef disrupts MHC-I trafficking by recruiting AP-1 to the MHC-I cytoplasmic tail. J. Cell Biol., 2004, 167, 903-913.
173. Lu, T.C.; He, J.C.; Wang, Z.H.; Feng, X.; Fukumi-Tominaga, T.; Chen, N.; Xu, J.; Iyengar, R.; Klotman, P.E. HIV-1 Nef disrupts the podocyte actin cytoskeleton by interacting with diaphanous interacting protein. J. Biol. Chem., 2008, 283, 8173-8182.
174. Betzi, S.; Restouin, A.; Opi, S.; Arold, S.T.; Parrot, I.; Guerlesquin, F.; Morelli, X.; Collette, Y. Protein protein interaction inhibition (2P2I) combining high throughput and virtual screening: Application to the HIV-1 Nef protein. Proc. Natl. Acad. Sci. U.S.A., 2007, 104, 19256-192561.
175. Kovaleski, B.J.; Kennedy, R.; Hong, M.K.; Datta, S.A.; Kleiman, L.; Rein, A.; Musier-Forsyth, K. In vitro characterization of the interaction between HIV-1 Gag and human lysyl-tRNA synthetase. J. Biol. Chem., 2006, 281, 19449-19456.
176. Salgado, G.F.; Marquant, R.; Vogel, A.; Alves, I.D.; Feller, S.E.; Morellet, N.; Bouaziz, S. Structural studies of HIV-1 Gag p6ct and its interaction with Vpr determined by solution nuclear magnetic resonance. Biochemistry, 2009, 48, 2355-2367.
177. Spearman, P. HIV-1 assembly and cellular trafficking pathways: current understanding and potential for future therapeutics. Future HIV Ther., 2007, 1, 113-122.
178. Gao, Y.; Wang, R.; Lai, L. Structure-based method for analyzing protein-protein interfaces. J. Mol. Model, 2004, 10, 44-54.
179. Choi, S.K. Synthetic multivalent molecules: concepts and biomedical applications. New York: John Wiley & Sons; 2004. 49-63.